J. Carpten

发表

Integrating the Genetics of Race and Ethnicity Into Cancer Research: Trailing Jane and John Q. Public.

L. Newman, J. Carpten, 2018, JAMA surgery.

Strategies to Increase Participation of African Populations in Clinical Trials.

P. Loehrer, D. Shamley, J. Carpten, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Alveolar epithelial type 1 cells serve as a cell of origin for lung adenocarcinoma with distinct molecular and phenotypic presentation

T. Jashashvili, T. Stueve, D. Mullen, 2022, bioRxiv.

Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.

S. Edge, K. Nepple, J. Hopkins, 2023, JCO precision oncology.

Mitochondrial biology and prostate cancer ethnic disparity

M. Stern, P. Cohen, F. Odedina, 2018, Carcinogenesis.

Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias

James M. Bogenberger, J. Carpten, C. Beaudry, 2015, Investigational New Drugs.

Comparing the Utility of Mitochondrial and Nuclear DNA to Adjust for Genetic Ancestry in Association Studies

P. Cohen, Su-Jeong Kim, J. Wan, 2019, Cells.

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.

K. D. Sørensen, J. Witte, D. Schaid, 2023, American journal of human genetics.

Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma

T. Jashashvili, T. Stueve, B. Zhou, 2023, Cell reports.

Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry

K. D. Sørensen, J. Witte, D. Schaid, 2023, medRxiv.

The era of precision oncogenomics

E. Mardis, J. Carpten, 2018, Cold Spring Harbor molecular case studies.

Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers

A. Ratan, A. Tarhini, Islam Eljilany, 2024, Journal of Oncology Research and Therapy.

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

A. Ratan, A. Tarhini, Islam Eljilany, 2024, medRxiv.

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

K. D. Sørensen, Jacob M. Keaton, R. Mägi, 2023, Nature Genetics.